we studied the renal effects of nicardipine , a calcium entry blocker , in eight patients with essential hypertension ( group a , who i or ii ) , six hypertensive type ii diabetics with mild-to-moderate nephropathy ( group b , urinary albumin 200-789 mg/day ) , and six hypertensive type ii diabetics with severe or advanced nephropathy ( group c , urinary albumin 1,596-4,300 mg/day ) .
C0022646
renal
C0848548
hypertensive